Evaluation of gastrointestinal leakage using serum (1→3)-β-D-glucan in a Clostridium difficile murine model

FEMS Microbiology Letters

Volumn 363, Issue 18, 2016, Pages

  Leelahavanichkul, Asada ^a   Panpetch, Wimonrat ^a   Worasilchai, Navaporn ^a   Somparn, Poorichaya ^a   Chancharoenthana, Wiwat ^b   Nilgate, Sumanee ^a   Finkelman, Malcolm ^c   Chindamporn, Ariya ^a   Tumwasorn, Somying ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULABHORN GRADUATE INSTITUTE   (Thailand)

^c Associates of Cape Cod Inc   (United States)

Author keywords

(1 3) D glucan; Clostridium difficile; Gastrointestinal leakage; Murine model

Indexed keywords

BETA 1,3 GLUCAN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; MACROPHAGE INFLAMMATORY PROTEIN 2; PROBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA GLUCAN; BIOLOGICAL MARKER; CXCL2 CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTEREMIA; BACTERIAL COUNT; CANDIDA ALBICANS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS RHAMNOSUS; LETTER; MALE; MORTALITY RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; ANIMAL; BLOOD; DIARRHEA; DISEASE MODEL; EVALUATION STUDY; GASTROINTESTINAL TRACT; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PERMEABILITY; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-GLUCANS; BIOMARKERS; CHEMOKINE CXCL2; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL TRACT; LACTOBACILLUS RHAMNOSUS; MALE; MICE; MICE, INBRED ICR; PERMEABILITY; PROBIOTICS; ROC CURVE;

EID: 84991035946     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnw204     Document Type: Letter

References (41)

1. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006;55:1512-20.
2. Boonma P, Spinler JK, Venable SF et al. Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficileinduced IL-8 production by colonic epithelial cells. BMC Microbiol 2014;14:177.
3. Chang JY, Antonopoulos DA, Kalra A et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficileassociated diarrhea. J Infect Dis 2008;197:435-8.
4. Chen X, Katchar K, Goldsmith JD et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008;135:1984-92.
5. Chiba M, Mikami K, Iizuka M et al. Elevated plasma (1→3)-beta-D-glucan, a fungal cell wall constituent, in a subgroup of Crohn disease. Scand J Gastroentero 2001;36:447-8.
6. Daruwala C, Mercogliano G, Newman G et al. Bacteremia due to Clostridium difficile: case report and review of the literature. Clin Med Case Rep 2009;2:5-9.
7. Evans CT, Safdar N. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 2015;60 (Suppl.2):S66-71.
8. Finkelman M, Tamura H. Detection and measurement of (1→3)-β-D-glucan with Limulus amebocyte lysate-based reagents. In: Young SH, Castranova V (eds). Toxicity of 1→3-Beta-glucan, Glucans as a Marker of Fungal exposure. London: Taylor & Francis, 2005, 179-97.
9. Garcia-Lechuz JM, Hernangomez S, Juan RS et al. Extra-intestinal infections caused by Clostridium difficile. Clin Microbiol Infec 2001;7:453-7.
10. Guo Y, Zhou G, He C et al. Serum levels of lipopolysaccharide and 1,3-beta-D-glucan refer to the severity in patients with Crohn's Disease. Mediat Inflamm 2015;2015:843089.
11. Hurley JC, Guidet B, Offenstadt G et al. Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders. Crit Care 2012;16:R148.
12. Hutton ML, Mackin KE, Chakravorty A et al. Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett 2014;352:140-9.
13. Iliev ID, Funari VA, Taylor KD et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012;336:1314-7.
14. Jung E, Perrone EE, Liang Z et al. Cecal ligation and puncture followed by methicillin-resistant Staphylococcus aureus pneumonia increases mortality in mice and blunts production of local and systemic cytokines. Shock 2012;37:85-94.
15. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. New Engl J Med 1994;330:257-62.
16. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998;66:2018-25.
17. Klarin B, Molin G, Jeppsson B et al. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008;12:R136.
18. Lee NY, Huang YT, Hsueh PR et al. Clostridium difficile bacteremia, Taiwan. Emerg Infect Dis 2010;16:1204-10.
19. Leelahavanichkul A, Worasilchai N, Wannalerdsakun S et al. Gastrointestinal leakage detected by serum (1→3)-beta-Dglucan in mouse models and a pilot study in patients with sepsis. Shock 2016.
20. LefflerDA, Lamont JT. Clostridium difficile infection. NewEngl J Med 2015;372:1539-48.
21. Li XQ, Zhu YH, Zhang HF et al. Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances. PLoS One 2012;7:e40666.
22. Libby DB, Bearman G. Bacteremia due to Clostridium difficile-review of the literature. Int J Infect Dis 2009;13:e305-9.
23. Lichtman JS, Ferreyra JA, Ng KM et al. Host-microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep 2016;14:1049-61.
24. Lu M, Munford RS. The transport and inactivation kinetics of bacterial lipopolysaccharide influence its immunological potency in vivo. J Immunol 2011;187:3314-20.
25. Matarese LE, Kandil HM. Preventing bacteria-induced disease with bacteria. Nutr Clin Pract 2012;27:242-6.
26. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open 2014;4:e005047.
27. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008;46:1930-1.
28. Millon L, Grenouillet F, Crouzet J et al. False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrowtransplant recipient with GVH disease. Med Mycol 2010;48:661-4.
29. Netea MG, Joosten LA, van der Meer JW et al. Immune defence against Candida fungal infections. Nat Rev Immunol 2015;15:630-42.
30. Ollech JE, Shen NT, Crawford CV et al. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Cl Ga 2016;30:111-8.
31. RuhnkeM, Bohme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines from the infectious diseases working party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012;23:823-33.
32. Samonis G, Anastassiadou H, Dassiou M et al. Effects of broadspectrum antibiotics on colonization of gastrointestinal tracts of mice by Candida albicans. Antimicrob Agents Ch 1994;38:602-3.
33. Skraban J, Dzeroski S, Zenko B et al. Changes of poultry faecal microbiota associated with Clostridium difficile colonisation. Vet Microbiol 2013;165:416-24.
34. Sun X,Wang H, Zhang Y et al. Mouse relapse model of Clostridium difficile infection. Infect Immun 2011;79:2856-64.
35. Vincent C,Manges AR. Antimicrobial use, human gutmicrobiota and Clostridium difficile colonization and infection. Antibiotics 2015;4:230-53.
36. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247-63.
37. Wen K, Li G, Bui T et al. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. Vaccine 2012;30:1198-207.
38. Worasilchai N, Leelahavanichkul A, Kanjanabuch T et al. (1&ratt3)-beta-D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study. Med Mycol 2015;53:338-46.
39. Yamaguchi N, Sonoyama K, Kikuchi H et al. Gastric colonization of Candida albicans differs in mice fed commercial and purified diets. J Nutr 2005;135:109-15.
40. Zekovic DB, Kwiatkowski S, Vrvic MM et al. Natural and modified (1→3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol 2005;25:205-30.
41. Zhang L, Li N, Caicedo R et al. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alphainduced interleukin-8 production in Caco-2 cells. J Nutr 2005;135:1752-6.